Informing selection of drugs for COVID-19 treatment through adverse events analysis

Abstract Coronavirus disease 2019 (COVID-19) is an ongoing pandemic and there is an urgent need for safe and effective drugs for COVID-19 treatment. Since developing a new drug is time consuming, many approved or investigational drugs have been repurposed for COVID-19 treatment in clinical trials. T...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wenjing Guo, Bohu Pan, Sugunadevi Sakkiah, Zuowei Ji, Gokhan Yavas, Yanhui Lu, Takashi E. Komatsu, Madhu Lal-Nag, Weida Tong, Tucker A. Patterson, Huixiao Hong
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/cec1715e9fd24f53a1ff4e77983d08f9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!